Story
1 Mar 2005
GlaxoSmithKline, AstraZeneca, Merck, Pfizer & other firms join UK govt. in committing to increased access to essential medicines for poorest countries, including via differential pricing
See all tags
See all tags
Abbott Laboratories
AstraZeneca
Amgen
Bristol-Myers Squibb
Chiron
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Merck
Merck Sharp & Dohme (part of Merck)
Novartis
Pfizer
Procter & Gamble
Roche
Ranbaxy Laboratories
Schering-Plough
Shire
Tibotec (part of Johnson & Johnson)
Wyeth (part of Pfizer)
Janssen Pharmaceutica (part of Johnson & Johnson)
Restricted access to medicines
Illness
Intellectual Property
Protection of Reputation
OECD Guidelines
Guidelines by Governments
G7
WHO
EU & European Parliament
World Bank
World Trade Organisation (WTO)
Personal Health
Trade
Company Reporting
Company Support for Initiatives Promoting Development, Economic and Social Rights